Effects of secondary amyloidosis on arteriovenous hemodialysis fistula outcomes and intradialytic hypotension: A case-control study

Basit Öğe Kaydı
dc.contributor.authorSolak, Yalcin
dc.contributor.authorCaymaz, Memduh
dc.contributor.authorTonbul, Halil Zeki
dc.contributor.authorOzbek, Orhan
dc.contributor.authorTurkmen, Kultigin
dc.contributor.authorGormus, Niyazi
dc.date.accessioned2020-03-26T18:25:19Z
dc.date.available2020-03-26T18:25:19Z
dc.date.issued2012
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractAmyloid fibrils can affect vascular structure through deposition and by causing nitric oxide depletion and increase of asymmetric dimethyl arginine. Patients with amyloidosis are prone to development of hypotension. Hypotension may also affect the maturation of arteriovenous fistula (AVF) and may set the stage for formation of thrombosis and fistula failure. Thus, we aimed to evaluate effects of secondary amyloidosis on AVF outcomes and intradialytic hypotension. This is a case-control study which included 20 hemodialysis patients with amyloidosis and 20 hemodialysis patients without amyloidosis as control group. All patients underwent Doppler ultrasound of AVF. A thorough fistula history and baseline laboratory values along with episodes of intradialytic hypotension and blood pressure measurements were recorded. There was no difference between the groups regarding age, gender, body mass index, presence of comorbidities, hypertension, and drug use. Systolic and diastolic blood pressures were similar (119 +/- 28/75 +/- 17 and 120 +/- 14/75 +/- 10?mmHg for patients with and without amyloidosis, respectively). Intradialytic hypotension episodes were also similar. Patients with amyloidosis had significantly lower serum albumin and higher C-reactive protein values compared to control hemodialysis patients. AVF sites and total number of created fistulas were similar in both groups. Flow rates of current functional AVFs were not different between the groups (1084 +/- 875 and 845 +/- 466?mL/minute for patients with and without amyloidosis, respectively, p:0.67). Patency duration of first AVF was not different between the groups. Clinical fistula outcomes and rate of intradialytic hypotension episodes were not significantly different between patients with and without secondary systemic amyloidosis.en_US
dc.identifier.doi10.1111/j.1542-4758.2012.00673.xen_US
dc.identifier.endpage406en_US
dc.identifier.issn1492-7535en_US
dc.identifier.issue3en_US
dc.identifier.pmid22360544en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage401en_US
dc.identifier.urihttps://dx.doi.org/10.1111/j.1542-4758.2012.00673.x
dc.identifier.urihttps://hdl.handle.net/20.500.12395/27990
dc.identifier.volume16en_US
dc.identifier.wosWOS:000305946000009en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWILEY-BLACKWELLen_US
dc.relation.ispartofHEMODIALYSIS INTERNATIONALen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectArteriovenous fistulaen_US
dc.subjecthemodialysisen_US
dc.subjecthypotensionen_US
dc.subjectsecondary amyloidosisen_US
dc.titleEffects of secondary amyloidosis on arteriovenous hemodialysis fistula outcomes and intradialytic hypotension: A case-control studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu